
    
      A phase Ib, single-centre, dose-escalation trial with a traditional escalation rule with
      fixed dose levels ("3 + 3" rule). The recommended phase II dose will be defined as the
      maximum predefined dose level at which 0 of 3 or â‰¤ 1 of 6 subjects experience a drug-related
      dose limiting toxicity (DLT) during cycle 1 and 2 of treatment. An estimated 10-20 patients
      will be required for this study.
    
  